Riddle & Riddle Injury Lawyers | December 19, 2025 | Dangerous Drugs
A significant development has emerged in the rapidly expanding litigation surrounding GLP-1 receptor agonist drugs such as Ozempic. The U.S. Judicial Panel on Multidistrict Litigation (JPML) has officially created a new federal multidistrict litigation (MDL) focused specifically on claims that these medications caused non-arteritic anterior ischemic optic neuropathy (NAION) — a serious and often permanent form of vision loss.
This decision marks an important turning point for patients who allege that GLP-1 drugs caused sudden optic nerve damage and irreversible blindness. By separating these cases from existing GLP-1 lawsuits, the court has acknowledged that vision loss claims raise distinct medical, scientific, and legal issues that warrant their own focused proceeding.
Below, we break down what this new MDL means, why it matters, and what individuals should know if they or a loved one experienced vision loss after using a GLP-1 medication.
What Is the New GLP-1 Vision Loss MDL?
The JPML has established MDL No. 3163, titled In re: GLP-1 Receptor Agonists Products Liability Litigation (NAION). The MDL has been centralized in the U.S. District Court for the Eastern District of Pennsylvania, where it will be overseen by Judge Karen S. Marston.
This MDL consolidates federal lawsuits filed across the country that allege GLP-1 receptor agonist drugs — commonly prescribed for type 2 diabetes and weight loss — caused NAION, a condition that damages the optic nerve and can result in sudden, permanent vision loss.
Centralization enables a single judge to manage pretrial proceedings, coordinate discovery, and resolve common legal and scientific issues, thereby promoting efficiency while ensuring consistent outcomes across cases.
Why the JPML Created a Separate MDL for NAION Claims
One of the most important aspects of this decision is what the JPML did not do.
The Panel declined to include vision loss cases in the existing GLP-1 MDL, which is currently focused on weight loss drug lawsuits related to gastrointestinal injuries such as gastroparesis and intestinal obstruction. Instead, the court determined that NAION constitutes a distinct injury that requires its own litigation track.
The JPML found that NAION cases share common factual questions involving:
- Drug development and clinical testing
- Marketing and promotional practices
- Labeling and warning decisions
- Regulatory history and FDA interactions
- Scientific evidence linking GLP-1 drugs to optic nerve injury
Because the medical mechanisms, risk profiles, and damages associated with permanent vision loss differ significantly from those of gastrointestinal claims, the court concluded that combining them would be inefficient and potentially unfair to plaintiffs.
This separation is critical for injured patients. It ensures that NAION claims receive focused judicial attention, rather than being overshadowed by broader GLP-1 litigation. If you believe you or a loved one have suffered vision loss (NAION) potentially due to use of weight loss / diabetes drugs, call 1-800-525-7111 for a FREE case review.
Understanding NAION and Why These Claims Are So Serious
Non-arteritic anterior ischemic optic neuropathy is a condition caused by reduced blood flow to the optic nerve. It often occurs suddenly, without warning, and may lead to partial or complete vision loss in one eye.
Key characteristics of NAION include:
- Sudden vision loss, often upon waking
- Permanent damage with no proven treatment to restore vision
- Increased risk of vision loss in the other eye
- Significant impact on quality of life, independence, and ability to work
For many patients, the damage is life-altering and irreversible.
Plaintiffs in this MDL allege that GLP-1 drugs increased the risk of NAION and that manufacturers failed to adequately warn patients and health care providers about this potential danger.
GLP-1 Drugs Involved in Vision Loss Allegations
While Ozempic is frequently mentioned in connection with these claims, the MDL is expected to encompass lawsuits involving multiple GLP-1 receptor agonist medications, including those prescribed for diabetes management and weight loss.
These drugs have surged in popularity in recent years, often marketed as effective and relatively safe options for metabolic conditions. Plaintiffs allege that critical safety risks related to optic nerve damage were not sufficiently disclosed, leaving patients unaware of the potential for catastrophic vision loss.
What Happens Next in MDL No. 3163?
Now that the MDL has been created, the litigation will move into an organized pretrial phase. This typically includes:
- Selection of leadership counsel for plaintiffs
- Coordinated discovery into internal company documents
- Expert review of medical and scientific evidence
- Development of “bellwether” cases to test claims before juries
Early bellwether cases help both sides evaluate the strengths and weaknesses of the litigation and often influence settlement discussions.
It is important to understand that an MDL is not a class action. Each plaintiff retains an individual case and must prove their own injuries and damages. However, shared evidence and rulings apply across cases, improving efficiency and consistency.
What This Means for Victims of GLP-1-Induced Vision Loss
For individuals who experienced sudden vision loss after using a GLP-1 medication, this MDL represents an important opportunity to pursue accountability.
You do not need to live in Pennsylvania or file your case in that state. If your lawsuit is filed in federal court, it may be transferred into the MDL for pretrial proceedings while still preserving your individual claim.
Because NAION often results in permanent impairment, damages in these cases may include:
- Medical expenses and ongoing care
- Loss of income or earning capacity
- Loss of independence and daily functioning
- Pain, suffering, and emotional distress
Given the complexity of pharmaceutical litigation and the scientific issues involved, it is critical to speak with a law firm experienced in handling national MDLs and serious injury claims.
How Riddle & Riddle Injury Lawyers Can Help
At Riddle & Riddle Injury Lawyers, we closely monitor major litigation developments that affect patients and families across the country. The creation of a separate MDL for GLP-1 vision loss claims underscores how seriously the courts are taking these allegations.
If you or a loved one suffered sudden or permanent vision loss after using Ozempic or another GLP-1 receptor agonist, you may have legal options. Our experienced dangerous drug attorneys can help evaluate your situation, explain how the MDL process works, and determine whether you may qualify to pursue a claim. We are ready to help however we can. Our attorneys have recovered over $900 million in compensation for our valued clients since 2000 alone (see disclaimer below), and we’re proud to be named a “Best Family-Run Law Firm” in 2025 by NC Lawyers Weekly.
Call Riddle & Riddle Injury Lawyers today for a free case review at 1-800-525-7111. There are no upfront costs, and no attorney fees unless we win your case and you receive compensation.
When Justice Counts™, count on the team at Riddle & Riddle.